Free Trial
NASDAQ:WINT

Windtree Therapeutics Q2 2025 Earnings Report

Windtree Therapeutics logo
$0.07 -0.01 (-8.87%)
As of 03:56 PM Eastern

Windtree Therapeutics EPS Results

Actual EPS
-$3.06
Consensus EPS
-$99.00
Beat/Miss
Beat by +$95.94
One Year Ago EPS
N/A

Windtree Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$3.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Windtree Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 19, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Windtree Therapeutics' Q3 2025 earnings is scheduled for Tuesday, November 25, 2025, with a conference call scheduled on Monday, November 24, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Windtree Therapeutics Earnings Headlines

The End of Elon Musk…?
While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the verge of its biggest breakthrough yet — a revolutionary form of “Manifested AI” that Forbes has called a multi-trillion-dollar opportunity, potentially sparking a 25,000% growth market and setting up what he believes could be the greatest corporate comeback in history.tc pixel
See More Windtree Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Windtree Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Windtree Therapeutics and other key companies, straight to your email.

About Windtree Therapeutics

Windtree Therapeutics (NASDAQ:WINT) is a clinical-stage biotechnology company developing innovative therapies for acute cardiovascular and pulmonary conditions. The company leverages its proprietary KL4 surfactant technology to address diseases marked by surfactant deficiency or dysfunction, with a primary focus on acute respiratory distress syndrome (ARDS) in adults and respiratory distress syndrome (RDS) in premature infants.

The company’s lead platform comprises synthetic peptide‐based surfactants designed to restore lung function by reducing surface tension in the alveoli. Windtree’s pipeline includes aerosolized and intratracheal formulations intended for rapid distribution in the lung, including programs that have advanced through preclinical studies and early-stage clinical trials. These programs aim to offer an alternative to animal-derived surfactants and to target patient populations with significant unmet medical needs.

Headquartered in Warrington, Pennsylvania, Windtree collaborates with academic research centers and clinical investigators across the United States and Europe to conduct its development programs. The company’s activities encompass formulation optimization, toxicology testing, and multi-site clinical evaluations, supported by partnerships that extend its reach into critical care and neonatal intensive care settings.

Under the leadership of President and CEO Michael Ott, Windtree maintains a management team with extensive experience in drug development, regulatory affairs and commercial strategy. The organization is committed to advancing its pipeline through regulatory interactions and clinical milestones in pursuit of therapies that can improve outcomes for patients with serious cardiopulmonary disorders.

View Windtree Therapeutics Profile

More Earnings Resources from MarketBeat